We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PGD for aneuploidy: CGH.
- Authors
Gianaroli, L.; Magli, M. C.; Ferraretti, A. P.; Muzii, L.; Crivello, A. M.; Stanghellini, I.
- Abstract
The microarray technology has recently entered CGH allowing for the analysis of the full set of 23 pairs of chromosomes in a few hours without the need for embryo cryopreservation. Because this is a new form of screening and has only been used in a small number of cases, it is not yet possible to say how successful and reliable it is. A novel study has been organized by ESHRE PGS Task Force [1] with the end point of defining the efficiency and reliability of this technique. The initial standardization phase implied a pilot study in which specific objectives included (1) completing the analysis within a time period that allows for fresh transfer, and (2) ensuring the reliable identification of the chromosomal status of an oocyte in at least 90% of polar body biopsy attempts. The experimental phase included the biopsy of approximately 300 oocytes fertilized after ICSI from which, expecting a 50% aneuploidy rate, another 150 aneuploid oocytes would be processed for array analysis to verify the data obtained from the polar bodies. The study started in October 2009 in two selected centers (SISMER, Bologna Italy and University of Bonn, Germany) having proven experience in the technique of polar body biopsy. The acquisition of the data from the intended number of biopsied oocytes will be terminated by the end of March 2010. The images of the arrays were scored by two independent observers in each centre. To estimate the concordance of the data from the polar bodies and the corresponding oocytes, there was a blind analysis of those oocytes which were assessed as aneuploid based on the result of the chromosomal analysis of their polar bodies. According to the established protocol, the oocytes destined to be analyzed were amplified in the center where they had been generated and the amplified product was shipped to the other center where labelling, hybridization and analysis were performed in a totally blind manner. It was decision of each center to analyze also oocytes in which the polar body testing was inconclusive. All data will be evaluated by an independent data analysis team (University of Amsterdam). The concordance analysis will be made on the basis of the categories euploid/aneuploid/unknown with the aim of having at least 90% concordance. If the results from the pilot study fulfil the expected requirements, a multicentre randomized trial will follow to test the clinical validity of the technique.
- Publication
Reproductive BioMedicine Online (Reproductive Healthcare Limited), 2010, Vol 20, pS8
- ISSN
1472-6483
- Publication type
Academic Journal
- DOI
10.1016/S1472-6483(10)62282-1